Vizsgálati helyszín
Santiago
Santiago, Reg Metropolitana de Santiago 8420383, ChileMég nincs intézményhez kötve
- 17futó vizsgálat
- 21lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 38 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 2. fázis19 vizsgálat
- 3. fázis16 vizsgálat
- 1/2. fázis1 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Lezárult15 vizsgálat
- Fut, nem toboroz13 vizsgálat
- Leállították6 vizsgálat
- Toboroz4 vizsgálat
Futó vizsgálatok
Toboroz
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT07170917· 2. fázis· Sanofi· Forrás
Toboroz
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196· 3. fázis· Sanofi· Forrás
Toboroz
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222· 3. fázis· Sanofi· Forrás
Toboroz
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule
NCT06812988· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
NCT06557772· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· 2/3. fázis· Sanofi· Forrás
Fut, nem toboroz
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
NCT05039840· 2. fázis· Sanofi· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Leállították
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
NCT06444451· 2. fázis· Sanofi· Forrás
Lezárult
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
NCT06224348· 3. fázis· Sanofi· Forrás
Lezárult
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
NCT06208306· 3. fázis· Sanofi· Forrás
Lezárult
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06130566· 3. fázis· Sanofi· Forrás
Leállították
Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06118099· 2. fázis· Sanofi· Forrás
Lezárult
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
NCT06073119· 2. fázis· Sanofi· Forrás
Lezárult
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
NCT05849922· 2. fázis· Sanofi· Forrás
Lezárult
Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma
NCT05421598· 2. fázis· Sanofi· Forrás
Lezárult
Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma
NCT05104892· 2. fázis· Sanofi· Forrás
Lezárult
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
NCT05104567· 2. fázis· Sanofi· Forrás
Lezárult
Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine
NCT05107115· 2. fázis· Sanofi· Forrás
Leállították
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
NCT05061420· 2. fázis· Sanofi· Forrás
Leállították
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
NCT04914897· 2. fázis· Sanofi· Forrás
Leállították
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
NCT04913220· 1/2. fázis· Sanofi· Forrás
Leállították
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
NCT04659603· 2. fázis· Sanofi· Forrás
Lezárult
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
NCT04751487· 3. fázis· Sanofi· Forrás
Lezárult
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
NCT04701983· 3. fázis· Sanofi· Forrás
Lezárult
Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)
NCT04572841· 2. fázis· Sanofi· Forrás
Lezárult
Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)
NCT04550962· Sanofi· Forrás
Lezárult
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
NCT04458051· 3. fázis· Sanofi· Forrás
Lezárult
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)
NCT04410991· 3. fázis· Sanofi· Forrás
Hibát jelzek